Table 5.
Baseline characteristic and therapy time of relapse and sustained response (SR) patients after discontinuation
| Characteristic | SR (n=45) | Relapse (n=19) | P value |
|---|---|---|---|
| HBV DNA - log10 IU/mL |
5.5±1.5 |
5.5±1.5 |
0.928 |
| ALT – × ULN |
3.0 (1.5-6.3) |
1.5 (1.2-5.1) |
0.154 |
| Age - years |
34±11 |
37±11 |
0.310 |
| Man - no. (%) |
34 (75.6) |
14 (73.7) |
0.874 |
| Time of achieving undetectable HBV DNA levels – weeks |
12 (12–24) |
16 (12–24) |
0.412 |
| Consolidation therapy - weeks |
120 (96–156) |
144 (96–144) |
0.798 |
| Genotype B - no. (%) |
19 (65.5) |
10 (34.5) |
0.445 |
| Genotype C - no. (%) | 26 (74.3) | 9 (25.7) |